RxDoctor Payments Data

Austin Luker

Child & Adolescent Psychiatry · Opelika, ALNPI 1790172385

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.

$1,215in general payments, 2019–2025

Across 58 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$203
  • Axsome Therapeutics, Inc.$151
  • AbbVie$149
  • Otsuka America Pharmaceutical, Inc.$140
  • Alkermes, Inc.$139
  • Supernus Pharmaceuticals, Inc.$107
  • plus $326 from 8 others

What the payments were for

  • Food & beverage$1,215100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,215 in reported general payments places this provider in the 70th percentile of 40 child & adolescent psychiatry providers in Alabama.

See all child & adolescent psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$7,632
Medicare patients
30
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FetzimaLevomilnacipran Hcl11$5,377
Clozapine14$2,605
Perphenazine11$1,079
Duloxetine Hcl24$873
Bupropion XlBupropion Hcl26$845
Methylphenidate Hcl16$444
Buspirone Hcl24$328
Quetiapine Fumarate25$324
Sertraline Hcl17$268
Donepezil Hcl18$205
Alprazolam54$205
Trazodone Hcl17$192
Clonazepam36$172
Diazepam18$115
Lamotrigine15$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieFetzima$149$5,37711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 child & adolescent psychiatry providers in Alabama.

Other child & adolescent psychiatry in Opelika

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →